• Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a highly collegial group that is dedicated to the pursuit of excellence and advancement of critical care research in Canada.
  • Canadian Critical Care Trials Group
    The CCCTG has are more than 30 research programs underway and over 100 peer-reviewed publications to its credit, with direct impact on clinical practice in critical care.
  • Canadian Critical Care Trials Group
    The Canadian Critical Care Trials Group (CCCTG) is a national organization of more than 300 individuals with research interests in the management of the critically ill patient.
  • Canadian Critical Care Trials Group
    Endorsement by the CCCTG communicates our full commitment to ensure that the work is undertaken in a rigorous and ethical manner, and communicated in a timely and effective way.
Programs

Principal Investigator(s)

Andrew Seely, Christopher Bredeson

Coordinator(s)

Kaitlyn Chambers, Anna Fazekas

Status

Enrolling

THRRIVES - Temperature, Heart and Respiratory Rate Investigation along with Variability Evaluation a

Temperature, Heart and Respiratory Rate Investigation along with Variability Evaluation and Serum Biomarkers (THRRIVES) Study

Early diagnosis of infection is already known to be critical in saving lives in patients with severe infection. Research has demonstrated that altered heart rate variability (HRV) and respiratory rate variability (RRV) are present in association with age and illness (e.g. reduced degree and complexity of patterns of variation), and the degree of alteration correlates with severity of illness. HRV and RRV analyses are rooted in complex systems science and involve advance mathematical characterization of the degree and nature of patterns of variation of heart rate and respiration rate, respectively. In addition, serum biomarkers have been extensively studied for the specific identification of infection. The overall aim of this study is to establish improved daily risk stratification and early warning of infection by applying continuous HRV and RRV analysis and intermittent measurement of serum biomarkers in patients who have undergone chemotherapy followed by a bone marrow transplant and are at marked risk for infection. To achieve this goal, our principal aims are as follows: (1) derive and validate a composite predictive model based on altered HRV and/or RRV along with daily serum biomarker measurement that provides daily risk stratification (i.e. prediction) and early warning (i.e. detection) of infection; and (2) evaluate the capacity of rapidity and severity of reduction in variability (HRV and RRV) and biomarkers to predict subsequent severity of illness secondary to infection. Our team is pioneering this innovative area of investigation, has demonstrated feasibility and compelling preliminary data, and is poised for the development of a novel predictive tool and early warning system with potential widespread relevance and clinical application.

Participating Centers

Ottawa Hospital, General Campus